key: cord-0841300-f0s6s5nb authors: Finch, Caleb E; Kulminski, Alexander M title: The ApoE locus and COVID-19: are we going where we have been? date: 2020-08-10 journal: J Gerontol A Biol Sci Med Sci DOI: 10.1093/gerona/glaa200 sha: 7a6361a13b13685d49d3586e7ebda89bb9df61a7 doc_id: 841300 cord_uid: f0s6s5nb The association of ApoE4 as a risk factor in SARS-CoV-2 infections by Kuo et al. J Gerontol is discussed in terms of ApoE allele pleiotropies and potential interactions of neighboring genes on CH19q.13 that also influence risk of obesity, cardiovascular disease, and Alzheimer disease. M a n u s c r i p t 2 Four decades ago in 1985, alleles of apolipoprotein E (ApoE) ε2/ε3/ε4 became famous for explaining 16% of genetic variance in low-density lipoprotein cholesterol in the benchmark study of Sing and Davignon (1) : total blood cholesterol, low-density lipoprotein cholesterol, and Apolipoprotein B were elevated by ApoE ε4 (ApoE4) allele and lowered by ApoE ε2 (ApoE2). The adverse associations of ApoE4 with atherosclerosis and cardiovascular disease (CVD) (1) were extended to shortened longevity in 1987 (2) and then to risk of Alzheimer disease (AD) in 1993 (3) . The next year, ApoE2 was associated with lower incidence of AD and greater longevity (4, 5) . ApoE is synthesized body-wide in adipocytes, hepatocytes, brain astrocytes, and arterial wall macrophages with local roles in lipid transport that are critical for brain, immune and vascular functions. ApoE4 is the ancestral human gene (6, 7) from which ApoE3 and then ApoE2 evolved in the last 250,000 years (8) . The persistence of ApoE4 was hypothesized to be advantageous for lipophilic pathogens (9) . In fact, apoE4 benefits hepatitis C infections (10) , as well as survival in highly infectious environments (11) and cognitive functions (12, 13) . This year, the ApoE locus has shown a new face with the increased vulnerability of ApoE4 carriers to severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), particularly for later ages. We briefly summarize how pleiotropies of ApoE4 may mediate multiple morbidities that increase vulnerability, and consider genes in the ApoE cluster that may contribute to age-related host susceptibility. A c c e p t e d M a n u s c r i p t 3 Preexisting morbidities increase risk of COVID-19 infections and mortality: for young adults: diabetes, and obesity; for older people: diabetes and dementia (14, 15) . COVID-19 also damages the cardiovascular system with atrial fibrillation, ventricular arrhythmia, and disseminated coagulation (16) . These morbidities are also associated with variants in the ApoE gene cluster that we hypothesize are relevant to COVID-19. ApoE4 homozygotes have 2.2-fold higher risk for COVID-19 positivity and 4.3-fold more case-fatality after COVID-19 than ApoE3 homozygotes (17, 18) . Heterozygosity (ε3/ε4) was modestly associated with COVID-19 below linear dose dependence. Strong associations for ε4/ε4 with COVID-19 were not diminished by excluding dementia, hypertension, coronary heart disease (CHD), or type II diabetes. Based on these associations, Kuo et al. hypothesize that ApoE4 has recessive effects on COVID-19 outcomes and suggest that these effects are independent of these common age-related diseases. We discuss how ApoE allele pleiotropies can mediated COVID-19 infectivity and survival. The multiple ApoE alleles of humans are unique among primates, which are monomorphic for an ApoE protein that shares the R112 and R158 of human ApoE4 (12) . Unlike the hemoglobin variant relationship to malaria resistance, the wide variations of ApoE4 (e.g. 3-fold gradient from Mediterranean to Nordic countries) has not been linked to past environments. The ApoE locus has complex linkage disequilibrium (LD) structures (19, 20) differing by race/ethnic groups (21, 22). The variable AD risks suggest that ApoE be considered a 'major gene' rather than 'risk gene' (23) . We may consider complex haplotypes rather than single alleles predisposing to age-related diseases. Associations of ApoE with AD also involve the neighboring TOMM40 poly-thymine repeat polymorphism (rs10524523) in the 'ApoE gene cluster' CH19q13 ( Fig.1) , which can increase susceptibility to AD either independently, or in cis-combination with ApoE4 (24, 25). Additionally, Also, AD risks are increased by the haplotype of ApoE (rs405509_T and ApoE4) when both are in cis on the same chromosome (26) . Several complex haplotypes in the APOE gene cluster can alter AD A c c e p t e d M a n u s c r i p t 4 risk independently of ApoE4 (27) . We hypothesize that ApoE4 associations with COVID-19 extend to the ApoE gene complex with balancing detrimental and protective effects in haplotypes, and multiple gene-by-gene transcriptional interactions (28) . This approach could identify protective genes for COVID-19. ApoE2 also merits consideration in COVID-19, given its benefit to CVD and AD. CH19q19.13 includes other apolipoprotein genes, ApoC1-ApoC4-ApoC2 (29) . ApoC1 was first known for inhibiting cholesteryl ester transfer (CETP) (30) . Diabetes can impair ApoC1 functions (31), as does CVD with dyslipidemia (32) . ApoC4 also mediates triglyceride metabolism (33) . Genomewide association studies showed that ApoC1-ApoC4-ApoC2 modulate triglycerides and high-density lipoproteins (34) . Pleiotropies of ApoE alleles for dietary lipid absorption and uptake by fat, muscle, and brain cells (35) could include ApoC haplotypes. Cell infection by SARS-Cov-2 is mediated by binding to ACE2 (angiotensin converting enzyme 2), which is also a key component of the renin-angiotensin system (RAS) in blood pressure regulation. The cell types expressing ACE2 show relationships to organ pathology, and include intestinal epithelia, lung alveoli (36), myocardial pericytes (37) and nasal epithelial (38) . Drug candidates for SARC-Cov-2 protection include several senolytics that interact with ACE2 and CD26, another host receptor (39, 40) . Infections may involve indirect roles of ApoE alleles. Hepatitis virus C binds to the ApoE protein (41) . We ask, could ApoE also bind coronaviruses? Several ApoE cluster genes may interact with COVID-19, e.g. NECTIN2 (herpes receptor HHV1) and ApoC1 which, like ApoE, is in the HCV envelope (42) . Neighboring genes mediate inflammation (C5a receptor, IGFL1, RELB, TGFβ). AD risk haplotypes include ApoE and NECTIN2 SNPs (19) . ApoE cluster haplotypes associate with the same morbidities from CVD and obesity (43, 44) that increase vulnerability to A c c e p t e d M a n u s c r i p t A c c e p t e d M a n u s c r i p t A c c e p t e d M a n u s c r i p t M a n u s c r i p t 10 44. Kulminski Role of the apolipoprotein E polymorphism in determining normal plasma lipid and lipoprotein variation Apolipoprotein E polymorphism and atherosclerosis: insight from a study in octogenarians Binding of human apolipoprotein E to synthetic amyloid beta peptide: isoform-specific effects and implications for late-onset Alzheimer disease Protective effect of apolipoprotein E type 2 allele for late onset Alzheimer disease Genetic associations with human longevity at the APOE and ACE loci Arginine residues at codons 112 and 158 in the apolipoprotein E gene correspond to the ancestral state in humans The evolution of Alzheimer disease, the reproductive schedule, and apoE isoforms Apolipoprotein E variation at the sequence haplotype level: implications for the origin and maintenance of a major human polymorphism APOE alleles and lipophylic pathogens Apolipoprotein E-epsilon 4 protects against severe liver disease caused by hepatitis C virus Effect of APOE epsilon4 allele on survival and fertility in an adverse environment The Exposome in Human Evolution: From Dust to Diesel Apolipoprotein E4 influences growth and cognitive responses to micronutrient supplementation in shantytown children from northeast Brazil Preexisting Comorbidities Predicting COVID-19 and Mortality in the UK Biobank Community Cohort Obesity could shift severe COVID-19 disease to younger ages COVID-19 and the cardiovascular system: implications for risk assessment, diagnosis, and treatment options APOE e4 genotype predicts severe COVID-19 in the UK Biobank community cohort ApoE e4e4 genotype and mortality with COVID-19 in UK Biobank Genetic and regulatory architecture of Alzheimer's disease in the APOE region Comprehensive analysis of APOE and selected proximate markers for late-onset Alzheimer's disease: patterns of linkage disequilibrium and disease/marker association APOE region molecular signatures of Alzheimer's disease across races/ethnicities APOE and Alzheimer disease: a major gene with semi-dominant inheritance A TOMM40 variable-length polymorphism predicts the age of late-onset Alzheimer's disease New Genetic Approaches to AD: Lessons from APOE-TOMM40 Phylogenetics An APOE haplotype associated with decreased epsilon4 expression increases the risk of late onset Alzheimer's disease Non-coding variability at the APOE locus contributes to the Alzheimer's risk Buffering mechanisms in aging: a systems approach toward uncovering the genetic component of aging Localization of genes encoding apolipoproteins CI, CII, and E to the p13----cen region of human chromosome 19 Human apolipoprotein C-I accounts for the ability of plasma high density lipoproteins to inhibit the cholesteryl ester transfer protein activity Glycation of apolipoprotein C1 impairs its CETP inhibitory property: pathophysiological relevance in patients with type 1 and type 2 diabetes Constitutive inhibition of plasma CETP by apolipoprotein C1 is blunted in dyslipidemic patients with coronary artery disease Expression of a novel human apolipoprotein (apoC-IV) causes hypertriglyceridemia in transgenic mice Discovery and refinement of loci associated with lipid levels Coronavirus Disease 2019 and Stroke: Clinical Manifestations and Pathophysiological Insights The ACE2 expression in human heart indicates new potential mechanism of heart injury among patients infected with SARS-CoV-2 Expression of the SARS-CoV-2 Entry Proteins, ACE2 and TMPRSS2, in Cells of the Olfactory Epithelium: Identification of Cell Types and Trends with Age COVID-19 and chronological aging: senolytics and other anti-aging drugs for the treatment or prevention of corona virus infection? Candidate drugs against SARS-CoV-2 and COVID-19 Apolipoprotein E mediates attachment of clinical hepatitis C virus to hepatocytes by binding to cell surface heparan sulfate proteoglycan receptors Apolipoprotein C1: Its Pleiotropic Effects in Lipid Metabolism and Beyond A c c e p t e d M a n u s c r i p t 9